Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
The European Patent Office's recent grant of the '265 Patent to Enanta was published in the European Patent Bulletin today. The '265 Patent is based on Enanta's July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The '265 Patent is the European counterpart of U.S. Patent No. 11,358,953 (the '953 Patent) involved in ongoing U.S. litigation between Enanta and Pfizer Inc.
Under UPC procedures, a hearing on the infringement action is expected to occur within the UPC's published 12-month target, with the decision rendered within weeks thereafter. If the UPC determines there has been infringement, subsequent proceedings would be required to determine damages. All timelines remain subject to potential rights of appeal and other customary proceedings in European patent litigation.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ® (U.S.) and MAVIRET ® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit www.enanta.com for more information.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to Enanta's filing in the UPC of a suit against Pfizer Inc. and certain of its subsidiaries seeking a determination of liability for use and infringement of Enanta's patent and Enanta's expectations with respect to any further action with respect to such proceedings. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including those covering one or more of its product candidates, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta's senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta's reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in 'Risk Factors' in Enanta's Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Nvidia Stock Falls Despite Bullish Calls From KeyBanc and Susquehanna
This article first appeared on GuruFocus. Aug 20 Nvidia Corporation (NASDAQ:NVDA) shares fell about 2.5% on Wednesday morning even as two Wall Street firms raised their price targets ahead of the company's quarterly earnings report next week. Warning! GuruFocus has detected 5 Warning Signs with NVDA. KeyBanc Capital Markets lifted its target on the chipmaker to $215 from $190, while keeping an Overweight rating. Analyst John Vinh said he expects Nvidia to post strong fiscal second-quarter results for July but guide slightly below consensus for the October quarter. He noted that the company's outlook likely excludes revenue from China due to pending license approvals and uncertain timing. According to Vinh, including China could add an incremental $2 billion to $3 billion in sales, driven by the H20 and RTX6000D processors. Susquehanna also raised its price target, moving to $210 from $180, and kept a Positive rating. Analyst Christopher Rolland sees continued momentum across Nvidia's data center business. Consensus estimates call for Nvidia to earn $1.01 per share on revenue of $45.92 billion in the coming quarter. The company is scheduled to release results on Aug. 27. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
NBC News
22 minutes ago
- NBC News
Nasdaq, S&P 500 end lower as investors sell tech, buy less pricey sectors
The Nasdaq and S&P 500 fell on Wednesday as investors sold tech stocks and moved into less highly valued sectors, as they also awaited remarks from Federal Reserve officials at their Jackson Hole symposium this week. Tech stocks, which drove much of the recovery from Wall Street's April selloff, have been pulling back. The S&P 500 technology index .SPLRCTwas down on the day, while sectors such as energy, healthcare and consumer staples rose. 'A broader lens tells you it's more of a rotation than a true sell off,' said Allspring's senior portfolio manager, Bryant van Cronkhite. 'Tech valuations look extended in the context of inflated spending today. Number two, I would say that there are a lot of pockets of the market that look very attractive from a valuation standpoint and they've been broadly ignored.' According to preliminary data, the S&P 500 lost 16.40 points, or 0.26%, to end at 6,394.97 points, while the Nasdaq Composite lost 144.76 points, or 0.68%, to 21,170.19. The Dow Jones Industrial Average rose 1.48 points, or 0.00%, to 44,923.75. Analysts listing other factors behind the tech sell-off mentioned OpenAI CEO Sam Altman's comments last week about artificial intelligence stocks being 'in a bubble,' and a Massachusetts Institute of Technology study that showed many tech companies were struggling to translate AI into actual profits. Some investors also worried about government interference in the private sector. President Donald Trump's administration is looking into taking equity stakes in chip firms such as IntelINTC.O, weeks after unprecedented revenue-sharing deals with Nvidia and AMD. Nvidia, Advanced Micro Devices, Intel and Micron fell. Nvidia's quarterly results on August 27 are keenly awaited for clues on demand for artificial intelligence. Other megacap growth names such as Apple and Meta also came under pressure. Minutes from the Fed's July meeting, where interest rates were left unchanged, showed almost all policymakers viewed it as appropriate to maintain the target range for the federal funds rate at 4.25% to 4.50%, despite two dissenters. Fed Chair Jerome Powell is expected to speak on Friday at the central bank's annual conference in Jackson Hole, Wyoming. His remarks will be closely watched for policy signals. Investors have been pricing in a 25-basis-point rate cut in September, according to data compiled by LSEG. Meanwhile, investors also monitored Trump's call for the resignation of Fed Governor Lisa Cook, with the president citing allegations that she was involved in mortgage fraud. Earnings from big retailers, seen as a barometer for the health of the American consumer, are also due this week as sentiment has taken a hit from concerns that tariffs could drive prices higher. Target after the company named a new CEO and retained its annual forecasts that were lowered in May.
Time Magazine
22 minutes ago
- Time Magazine
Public Health Workers Criticize RFK Jr. After CDC Shooting
More than 750 public health workers sent a letter to Health Secretary Robert F. Kennedy Jr. on Wednesday, urging him to 'stop spreading inaccurate health information' and guarantee employees' safety, in the wake of a shooting at the headquarters of the Centers for Disease Control and Prevention (CDC) earlier this month. The letter—signed by both named and anonymous current and former staffers at the U.S. Department of Health and Human Services (HHS), CDC, and National Institutes of Health who noted they signed the letter in their 'own personal capacities'—said the attack on the CDC's headquarters in Atlanta on Aug. 8 'was not random.' 'The attack came amid growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization—and now, violence,' public health workers said in the letter, which was also addressed to members of Congress. 'CDC is a public health leader in America's defense against health threats at home and abroad. When a federal health agency is under attack, America's health is under attack. When the federal workforce is not safe, America is not safe.' The public health workers went on to accuse Kennedy, a prominent vaccine skeptic, of being 'complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information.' They cited several statements and actions that Kennedy has made in recent months, pointing to his claim that mRNA vaccines 'fail to protect effectively' against upper respiratory infections such as COVID-19—despite years of research showing that the shots are both safe and effective—and his announcement that HHS would be winding down mRNA vaccine development. They also condemned his decision to remove all the experts from a critical vaccine advisory committee. And they said some of Kennedy's past comments—such as claiming that there is a 'cesspool of corruption at CDC'—were 'sowing public mistrust' in the health agency. The public health workers expressed their wish to honor police officer David Rose, who was killed while responding to the attack on the CDC headquarters in August. HHS said in a statement to TIME that Kennedy 'is standing firmly with CDC employees—both on the ground and across every center—ensuring their safety and well-being remain a top priority.' The agency added that, after the shooting earlier this month, Kennedy traveled to Atlanta and called the CDC 'a shining star' among the world's health agencies. 'For the first time in its 70-year history, the mission of HHS is truly resonating with the American people—driven by President Trump and Secretary Kennedy's bold commitment to Make America Healthy Again,' HHS said. 'Any attempt to conflate widely supported public health reforms with the violence of a suicidal mass shooter is an attempt to politicize a tragedy.' Law enforcement officials said they found evidence that the suspect in the August shooting, who they identified as Patrick Joseph White of Georgia, blamed the COVID-19 vaccine for his health ailments. White was found dead at the scene, and authorities later said that he died of a self-inflicted gunshot wound. CDC Director Susan Monarez noted the dangers posed by misinformation in a staff meeting in the wake of the attack. 'We know that misinformation can be dangerous,' she said, according to NBC News. 'Not only to health, but to those that trust us and those we want to trust. We need to rebuild the trust together.' The day after the shooting, Kennedy expressed his condolences to Rose's family in a post on X. 'We know how shaken our public health colleagues feel today. No one should face violence while working to protect the health of others,' he said. 'We are actively supporting CDC staff on the ground and across the agency. Public health workers show up every day with purpose—even in moments of grief and uncertainty. We honor their service. We stand with them. And we remain united in our mission to protect and improve the health of every American.' Kennedy was one of President Donald Trump's most controversial Cabinet nominees, and faced heated questioning by Senators during his confirmation hearings. He has drawn outrage from the medical establishment in the past for spreading disinformation, including repeating the debunked claim that vaccines cause autism. In their letter, public health workers claimed Kennedy's 'dangerous and deceitful statements and actions have contributed to the harassment and violence experienced by CDC staff.' They implored him to take three steps by Sept. 2 to 'uphold his pledge to safeguard the health of the American public,' including asking him to 'stop spreading inaccurate health information,' particularly regarding vaccines, infectious disease transmission, and the country's public health institutions. They also urged him to affirm the scientific integrity of the CDC and guarantee the safety of HHS employees, such as through emergency procedures and alerts. 'The deliberate destruction of trust in America's public health workforce puts lives at risk,' they wrote in the letter. 'We urge you to act in the best interest of the American people—your friends, your families, and yourselves.'
